Vaxcyte Commences Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Strategic Insights -

Vaxcyte, a clinical-stage vaccine innovation company, has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering, which is subject to market and regulatory conditions, aims to raise funds to support the company's continued growth and development of its high-fidelity vaccines. Joint book-running managers for the offering include BofA Securities, Jefferies, SVB Securities, Evercore ISI, and Guggenheim Securities, while Cantor will act as lead manager and Needham & Company and BTIG as co-managers.

Key Takeaways:

  • Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect against bacterial diseases.
  • The company has commenced an underwritten public offering of its common stock and pre-funded warrants to raise funds for continued growth and development.
  • The offering is subject to market and regulatory conditions, and there is no guarantee as to whether or when it may be completed.
  • Vaxcyte's pipeline includes several vaccine candidates, including VAX-24, VAX-31, VAX-A1, VAX-PG, and VAX-GI, which are designed to treat or prevent various bacterial infections.
  • The company is re-engineering the vaccine development process through its advanced chemistry and XpressCF(TM) cell-free protein synthesis platform.

Statistics:

  • 30-day option to purchase up to an additional 15% of the number of shares of Vaxcyte's common stock offered in the public offering (including shares underlying the pre-funded warrants).
  • 24-valent pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease.
  • 15 joint book-running managers and co-managers participating in the underwritten public offering.

Sources:

  • LLC, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com
  • LLC, 520 Madison Avenue, New York, New York 10022, by telephone at 1-877-821-7388, or by email at Prospectus_Department@Jefferies.com
  • LLC, 53 State Street, 40th Floor, Boston, MA 02109, by email at syndicate@svbsecurities.com or by phone at (800) 808-7525, ext. 6105
  • L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200 or by email at ecm.prospectus@evercore.com
  • LLC, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com